XTRA:BAYNPharmaceuticals
Bayer (XTRA:BAYN) Teams Up With Kairos Pharma On Prostate Cancer Combo Study
Bayer (XTRA:BAYN) announced a collaboration with Kairos Pharma to study a combination of XOFIGO and the ENV-105 antibody for metastatic castration-resistant prostate cancer.
The partnership focuses on using ENV-105, which has shown potential in re-sensitizing tumors with a strong safety profile, alongside Bayer's approved radiopharmaceutical XOFIGO.
The agreement is aimed at advancing treatment options for patients with advanced prostate cancer and expanding Bayer's oncology efforts.
Bayer...